Apnex secures $16.1m in series A:
This article was originally published in Clinica
Executive Summary
Minneapolis, Minnesota-based Apnex Medical, a subsidiary of Prospex Medical, will finance the initiation of clinical studies of its implantable technology for the treatment of obstructive sleep apnea with $16.1m of private funding. Domain Associates, New Enterprise Associates, Polaris Venture Partners and Michael Berman, current active chairman of Apnex and co-founder of Prospex, all participated in the series A financing. Obstructive sleep apnea is the most significant form of a condition that causes restricted breathing during sleep. Sleep apnea affects an estimated 18 million Americans, according to the American Lung Association.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.